This real-world retrospective cohort study of adults with type 2 diabetes in Sweden, using analysis of data from the NDR linked with comprehensive prescribing information from the SPDR, has shown that adults with type 2 diabetes on intensive insulin therapy with multiple daily injections and adults with type 2 diabetes treated with basal insulin only achieve significant and comparable reductions in HbA1c 6 months after being prescribed isCGM, and these reductions persist for at least 24 months. The gene discussed is INS; the disease is type 2 diabetes mellitus.